Camber Spine Receives FDA Clearance for SPIRA-A Integrated Fixation System 
Pieris Pharmaceuticals to Host Full-Year 2018 Investor Call and Corporate Update on March 12, 2019
BOSTON, MA / ACCESSWIRE / March 5, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a biotechnology company advancing novel biotherapeutics...
Viveve to Present at Cowen and Company 39th Annual Health Care Conference
ENGLEWOOD, CO / ACCESSWIRE / March 5, 2019 / Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on...
Parallax Health Sciences Appoints Pete Scobell to Board of Advisors
Executive and former Navy SEAL brings leadership and telehealth marketing experience to Parallax SANTA MONICA, CA / ACCESSWIRE / March...
Women’s Risk of Colorectal Cancer Linked To Physical Inactivity
NEW YORK, NY / ACCESSWIRE / March 4, 2019 / Inactive and sedentary lifestyles have been consistently linked to both...
EViTRADE Appoints Investor Relations Firm – Updated
VANCOUVER, BC / ACCESSWIRE / March 4, 2019 / EVITRADE Health Systems Corp. (CSE: EVA, OTCQB: EVAHF) (the "Company") is...
“Together Hand in Hand”: 14th IFSSH & 11th IFSHT Triennial Congress for Hand Surgery and Therapy in Berlin
Berlin – From 17 to 21 June 2019, the International Federation of Societies for Surgery of the Hand (IFSSH) and...
CorMedix Inc. Appoints Alan W. Dunton, M.D. to Board of Directors
BERKELEY HEIGHTS, NJ / ACCESSWIRE / March 4, 2019 / CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on...
Invitation to Year-End Results 2018 Conference Call of MorphoSys AG on March 14, 2019
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / March 4, 2019 / MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX & MDAX; Nasdaq:...
EViTRADE Appoints Investor Relations Firm
VANCOUVER, BC / ACCESSWIRE / March 4, 2019 / EVITRADE Health Systems Corp. (CSE: EVA, OTCQB: EVAHF) (the "Company") is...
Adhera Therapeutics and Alyvant Enter into Digital Co-Promotion Agreement for Prestalia
RESEARCH TRIANGLE PARK, NC and NEW YORK, NY / ACCESSWIRE / March 4, 2019 / Adhera Therapeutics (OTCQB: ATRX), a...
Xenetic Biosciences, Inc. (NASDAQ: XBIO) Announces Agreement to Acquire Innovative CAR T Technology Platform
Innovative XCART platform with demonstrated proof of mechanism and preclinical evidence of target specificity positions Xenetic to address high value...
Savara to Present at the 39th Annual Cowen and Company Healthcare Conference
AUSTIN, TX / ACCESSWIRE / March 4, 2019 / Savara Inc. (NASDAQ: SVRA), an orphan lung disease company, announced today...
Soliton Receives FDA Approval for Small Business Designation
The Company qualifies for reduced or waived fees for medical device submissions with the FDA HOUSTON, TX / ACCESSWIRE /...
Theralase Granted United States Patent to Destroy Cancer Cells with X-Ray Activated Photo Dynamic Compounds
TORONTO, ONTRAIO / ACCESSWIRE / March 4, 2019 / Theralase Technologies Inc. ("Theralase®" or the "Company") (TSXV: TLT) (OTCQB: TLTFF),...
Intellipharmaceutics Announces Resubmission of New Drug Application to the U.S. FDA for its Oxycodone ER
TORONTO, ON / ACCESSWIRE / March 4, 2019 / Intellipharmaceutics International Inc. (NASDAQ: IPCI, TSX: IPCI) ("Intellipharmaceutics" or the "Company"),...
Avinger to Present at Oppenheimer Healthcare Conference on March 20
REDWOOD CITY, CA / ACCESSWIRE / March 1, 2019 / Avinger, Inc. (NASDAQ: AVGR), a leading developer of innovative treatments...
EyeGate Pharmaceuticals Reports Full Year 2018 Financial Results and Provides Business Update
WALTHAM, MA / ACCESSWIRE / March 1, 2019 / EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (''EyeGate'' or ''the Company'') today announced...
ITOCO – Camedco JV Creates Future Leader in Medical Cannabis
TORONTO, ON / ACCESSWIRE / February 27, 2019 / Itoco Inc (OTC PINK: ITMC), has signed a letter of intent...
Heat Biologics Presents Interim Phase 2 Lung Cancer Data on HS-110 + Nivolumab at ASCO-SITC Clinical Immuno-Oncology Symposium
- Preliminary data suggests the addition of HS-110 to Nivolumab may restore responsiveness to treatment after tumor progression on prior...
New Paper Relevant for the Optimal Development of Drugs Targeting LSD1 Published by ORYZON
Uses proprietary chemoprobe technology to demonstrate target engagement, key to drug development and rational dosing Useful to identify interaction partners...